Pliant Therapeutics Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Bernard Coulie

Geschäftsführender

US$11.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	5.5%
Amtszeit als Geschäftsführer	8.3yrs
Eigentum des Geschäftsführers	1.0%
Durchschnittliche Amtszeit des Managements	8.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.7yrs

Jüngste Management Updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07

Recent updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21

Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Dec 17

Pliant Therapeutics (PLRX) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow

Dec 02

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Bernard Coulie im Vergleich zu den Einnahmen von Pliant Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$171m
Dec 31 2023	US$11m	US$610k	-US$161m
Sep 30 2023	n/a	n/a	-US$155m
Jun 30 2023	n/a	n/a	-US$144m
Mar 31 2023	n/a	n/a	-US$133m
Dec 31 2022	US$11m	US$587k	-US$123m
Sep 30 2022	n/a	n/a	-US$113m
Jun 30 2022	n/a	n/a	-US$109m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$5m	US$556k	-US$97m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$2m	US$499k	-US$42m
Sep 30 2020	n/a	n/a	US$18m
Jun 30 2020	n/a	n/a	US$19m
Mar 31 2020	n/a	n/a	US$20m
Dec 31 2019	US$2m	US$428k	-US$7m

Vergütung im Vergleich zum Markt: BernardDie Gesamtvergütung ($USD11.17M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD3.40M).

Entschädigung vs. Einkommen: BernardDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Bernard Coulie (57 yo)

8.3yrs

Amtszeit

US$11,165,999

Vergütung

Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Director of Septerna, Inc. from February 2024. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairm...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Bernard Coulie	President	no data	US$11.17m	1.04% $ 6.7m
Keith Cummings	Chief Financial Officer	5.5yrs	US$4.44m	0.30% $ 1.9m
Mike Ouimette	General Counsel & Corporate Secretary	3.7yrs	US$3.32m	0.048% $ 313.2k
Johannes Hull	Chief Business Officer	8.3yrs	US$4.36m	0.30% $ 1.9m
Éric Lefebvre	Chief Medical Officer	6.1yrs	US$4.69m	keine Daten
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	9.4yrs	keine Daten	keine Daten
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	9.4yrs	keine Daten	keine Daten
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	9.4yrs	keine Daten	keine Daten
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	9.4yrs	keine Daten	keine Daten
Craig Muir	Interim Chief Technology Officer	no data	keine Daten	keine Daten
Christopher Keenan	Vice President of Investor Relations & Corporate Communications	no data	keine Daten	keine Daten
Lily Cheung	Chief Human Resources Officer	1.4yrs	keine Daten	0.0013% $ 8.5k

8.3yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: PLRXDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Bernard Coulie	President	8.3yrs	US$11.17m	1.04% $ 6.7m
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Gayle Crowell	Independent Director	4.5yrs	US$278.71k	0% $ 0
Brian Metcalf	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Suzanne Bruhn	Independent Director	7.9yrs	US$277.21k	0.058% $ 375.7k
John Curnutte	Independent Director	6.8yrs	US$271.96k	0.049% $ 313.5k
Hoyoung Huh	Independent Chairman	6.5yrs	US$296.71k	0.17% $ 1.1m
Smital Shah	Independent Director	5.3yrs	US$277.96k	0% $ 0
Bill Greenlee	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

6.7yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: PLRXDie Vorstandsmitglieder gelten als erfahren (6.7 Jahre durchschnittliche Amtszeit).

Pliant Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Chief Business Officer notifies of intention to sell stock

Recent updates

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 69%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.1% to US$42.67

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$44.08

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings released: US$0.69 loss per share (vs US$0.65 loss in 3Q 2022)

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Consensus revenue estimates fall by 32%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Business Officer notifies of intention to sell stock

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 123%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel & Corporate Secretary notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

President notifies of intention to sell stock

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Price target increased by 17% to US$49.09

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

President notifies of intention to sell stock

Insufficient new directors

General Counsel & Corporate Secretary notifies of intention to sell stock

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options and sold US$256k worth of stock

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics: Wait For A Better Price To Get In

Consensus revenue estimates increase by 48%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant's PLN-74809 gets FDA fast track status for liver disease

Price target increased to US$43.71

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant: Major Catalyst Expected Beginning Of 2023

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

Price target decreased to US$39.67

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers

Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis